Investigational drug · Phase 2
AZD2287
Also called: Imaging agent
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Metastatic Prostate Cancer.
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 14, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
3
Any phase or sponsor naming "AZD2287"
First trial start
2024
Mar 12, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "AZD2287", any sponsor or status.
Conditions studied
As listed on its trial records.
- Metastatic Prostate Cancer
Approved drugs for the same conditions: Prostate cancer · Oncology · Kidney and urology
Largest trials
Live from ClinicalTrials.gov: studies naming "AZD2287" as an intervention, largest first.
- Phase Ib/II Platform Study of Multiple Anti-Cancer Agents in Participants With Metastatic Prostate CancerPivotal-lookingRecruiting
AstraZenecaAstraZeneca (AZN)
NCT07590934 · 152 participants (planned) · Start Jun 3, 2026 · Primary completion Sep 25, 2029
Drug: AZD2265 (FPI-2265); Palacaparib (AZD9574) and 2 more · For: Metastatic Prostate Cancer
Sites: Duarte, California; Encino, California; South Pasadena, California · 38 sites in all
- A Phase I Study of [225Ac]-AZD2284 in Patients With Metastatic Castration-Resistant Prostate CancerRecruiting
AstraZenecaAstraZeneca (AZN)
NCT06879041 · 136 participants (planned) · Start Mar 10, 2025 · Primary completion Apr 16, 2029
Drug: AZD2287; AZD2275 and 1 more · For: Metastatic Castration-Resistant Prostate Cancer
Sites: Palo Alto, California; San Diego, California; Miami, Florida · 16 sites in all
AstraZenecaAstraZeneca (AZN)
NCT06267729 · 60 participants (planned) · Start Mar 12, 2024 · Primary completion Nov 24, 2026
Drug: AZD0754; AZD2287 · For: Metastatic Prostate Cancer
Sites: Duarte, California; Tampa, Florida; Atlanta, Georgia · 15 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Mucosa-penetrating NIR-II nanomedicine for precision photoimmunotherapy of bladder cancer.
Ding Y, Zhu Y, Li J, et al. · Biomaterials 2027
- Preclinical Studies of MVT-100, A Novel Ultrasound Enhancing Agent.
Meuillet EJ, Lusk J, Tadevich H, et al. · Ultrasound Med Biol 2027
- An artificial intelligence-assisted PARP-1-targeted PET imaging agent [68Ga]Ga-DOTA-FZPF: From bench to clinic.
Ji M, Jiang C, Xi Y, et al. · Mater Today Bio 2026
- Fibroblast-activation protein inhibitors based positron emission tomography (PET) for assessing lung disease: A systematic review with meta-analysis.
Huang D, Zhao Q, Wu J, et al. · Pulmonology 2026
- Cellular and molecular imaging of coronary atherosclerosis: clinical applications.
Jaffer FA, Dweck MR, Tearney GJ, et al. · Eur Heart J 2026
- Pudexacianinium chloride (ASP5354) for ureter visualization in patients undergoing abdominopelvic surgery: a phase III, multicenter, open-label, randomized study.
Albert M, Lautz TB, Allawi A, et al. · Surg Endosc 2026
Also in development for Metastatic Prostate Cancer
- PalacaparibAZD9574Phase 25 trials
AstraZeneca · Metastatic Prostate Cancer, Ovarian Cancer, Endometrial Cancer
- FPI-2265AZD2265, 225Ac-PSMA-I&TPhase 24 trials
Fusion Pharmaceuticals Inc. · Metastatic Castration-resistant Prostate Cancer, Metastatic Prostate Cancer, Metastatic Castration Resistant Prostate Cancer
- BalstilimabAGEN2034Phase 23 trials
ImmunoGenesis · Metastatic Prostate Cancer, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Pancreatic Cancer
- ZalifrelimabPhase 22 trials
ImmunoGenesis · Metastatic Prostate Cancer, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Pancreatic Cancer
- AZD0516Phase 21 trial
AstraZeneca · Metastatic Prostate Cancer
- AZD0754Phase 21 trial
AstraZeneca · Metastatic Prostate Cancer
- AZD8359Phase 21 trial
AstraZeneca · Metastatic Prostate Cancer
- GDC-1261Phase 21 trial
Roche (Genentech) · Advanced Prostate Cancer, Metastatic Prostate Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from AstraZeneca.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.